StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Protagonist Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was 29.4%. For fiscal 2025 it was -282.8%, against 63.3% the year before. The highest annual figure on record is 63.3% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-282.8%−346.2
FY2024Dec 31, 202463.3%+194.9
FY2023Dec 31, 2023-131.6%+347.7
FY2022Dec 31, 2022-479.3%−20.3
FY2021Dec 31, 2021-458.9%−227.9
FY2020Dec 31, 2020-231.1%+33183.2
FY2019Dec 31, 2019-33414.3%−33288.4
FY2018Dec 31, 2018-125.9%+58.3
FY2017Dec 31, 2017-184.2%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202676.3%+703.2
Q1 FY2026Mar 31, 20266.7%+47.9
Q4 FY2025Dec 31, 2025-596.8%−674.0
Q3 FY2025Sep 30, 2025-834.9%−124.5
Q2 FY2025Jun 30, 2025-627.0%+107.8
Q1 FY2025Mar 31, 2025-41.2%−122.5
Q4 FY2024Dec 31, 202477.2%+31.6
Q3 FY2024Sep 30, 2024-710.4%+4066.9
Q2 FY2024Jun 30, 2024-734.7%−653.4
Q1 FY2024Mar 31, 202481.3%+509.6
Q4 FY2023Dec 31, 202345.6%+374.2
Q2 FY2022Jun 30, 2022-4777.3%−3415.6
Q1 FY2022Mar 31, 2022-81.4%+306.4
Q4 FY2021Dec 31, 2021-428.3%−94.0
Q3 FY2021Sep 30, 2021-328.6%−269.4
Q2 FY2021Jun 30, 2021-1361.7%−718.0
Q1 FY2021Mar 31, 2021-387.8%+8.5
Q4 FY2020Dec 31, 2020-334.3%+569.8
Q3 FY2020Sep 30, 2020-59.2%+530.1
Q4 FY2019Dec 31, 2019-643.7%−500.9
Q3 FY2019Sep 30, 2019-396.3%−322.0
Q1 FY2019Mar 31, 2019-904.0%−833.0
Q4 FY2018Dec 31, 2018-589.2%−562.2
Q3 FY2018Sep 30, 2018-142.8%−87.9
Q2 FY2018Jun 30, 2018-74.2%–
Q1 FY2018Mar 31, 2018-71.1%–
Q4 FY2017Dec 31, 2017-27.1%–
Q3 FY2017Sep 30, 2017-54.9%–

More Protagonist Therapeutics figures

See a number that looks wrong?